Assuntos
Neoplasias da Mama/tratamento farmacológico , Lapatinib/administração & dosagem , Receptor ErbB-2/análise , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Feminino , Humanos , Terapia Neoadjuvante , Receptor ErbB-2/antagonistas & inibidores , Trastuzumab/administração & dosagemAssuntos
Neoplasias da Mama , Dimaprit/análogos & derivados , Seguimentos , Humanos , Paclitaxel , Receptor ErbB-2 , TrastuzumabAssuntos
Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/patologia , Linfonodos/diagnóstico por imagem , Linfonodos/patologia , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/métodos , Feminino , Humanos , Metástase Linfática , Linfocintigrafia/economia , Linfocintigrafia/métodos , Biópsia de Linfonodo Sentinela/economia , Biópsia de Linfonodo Sentinela/métodosAssuntos
Neoplasias da Mama , Mastectomia , Axila , Quimioterapia Adjuvante , Feminino , Humanos , Terapia NeoadjuvanteRESUMO
Cardiac myxomas are rare tumors. Esophageal adenocarcinomas are common tumors of the gastrointestinal tract. Simultaneous occurrence of these tumors has not been reported. A 52-year-old gentleman presented to our hospital with dysphagia and was diagnosed with esophageal adenocarcinoma. Routine echocardiography discovered a cardiac tumor in the left atrium. The cardiac tumor was surgically removed and biopsy confirmed a myxoma. We removed the cardiac tumor as the first step and then initiated neoadjuvant chemotherapy. It is ideal to constitute a multidisciplinary team to decide on the course of treatment in such cases.
Assuntos
Adenocarcinoma/patologia , Neoplasias Esofágicas/patologia , Junção Esofagogástrica/patologia , Neoplasias Cardíacas/patologia , Mixoma/patologia , Neoplasias Primárias Múltiplas/patologia , Adenocarcinoma/diagnóstico por imagem , Adenocarcinoma/terapia , Procedimentos Cirúrgicos Cardíacos , Quimioterapia Adjuvante , Ecocardiografia , Neoplasias Esofágicas/diagnóstico por imagem , Neoplasias Esofágicas/terapia , Junção Esofagogástrica/diagnóstico por imagem , Neoplasias Cardíacas/diagnóstico por imagem , Neoplasias Cardíacas/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Mixoma/diagnóstico por imagem , Mixoma/cirurgia , Terapia Neoadjuvante , Neoplasias Primárias Múltiplas/diagnóstico por imagem , Neoplasias Primárias Múltiplas/terapia , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
OBJECTIVE: To assess late clinical outcomes with image guided intensity modulated radiotherapy (IG- IMRT) in gynecological malignancies. PATIENTS AND METHODS: We have been practicing IG IMRT for gynecological malignancies since January 2009. Here we are presenting our experience with this modern technique at median follow up of 38 months. During whole treatment bladder filling protocol was followed. Both target volumes and critical structures were contoured according to RTOG guidelines. Dose prescribed to clinical target volume (postop bed and nodal volume) was 50.4 Gy in 28 fractions. Cone beam CT (CBCT) scans were taken to quantify the status of target volume and normal structures. RESULTS: 80 patients were evaluated and analyzed who were treated from January 2009 to December 2014. Median age of our patients was 56.5 years. Out of eighty, forty four patients (55%) were of carcinoma endometrium and the rest 36 (45%) were of carcinoma cervix. None of our patients experienced late grade 3 or 4 bladder toxicity. Although late grade 3 and 4 bowel and rectal toxicity was experienced by single patient. 2.5% patients developed local recurrence, 5% patient developed nodal with distant metastases and 6.25% only distant metastases. Three of our patients developed lung cancer as second primary during follow up. 76.2% atients are alive with regular follow up. CONCLUSIONS: Our study concluded that IG IMRT increases patient compliance and reduces long-term side effects in post-operative gynecological malignancies without compromising local-regional control, disease free survival and overall survival.